Abbvie Inc
NYSE: ABBV
$164.99
-$4.64 (-2.7%)
Closing Price on November 15, 2024
ABBV Articles
The January 15 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.
Published:
Last Updated:
The Wall Street firms we cover are well aware of investor anxiety, yet they, unlike financial media talking heads, realize investors can’t just go to cash with a snap of their fingers.
Published:
Last Updated:
The short interest data have been released for the December 31 settlement date. For most of the selected pharmaceutical stocks short interest was up.
Published:
Last Updated:
In a new research note, Jefferies makes the case that earnings could give a lift to the sagging market, and with low expectations, the lift could be solid.
Published:
Last Updated:
The short interest data have been released for the December 15 settlement date, and for most of the selected pharmaceutical stocks short interest was up.
Published:
Last Updated:
24/7 Wall St. screened the Jefferies Franchise Picks list for the top-yielding stocks and found four with outstanding growth potential.
Published:
Last Updated:
The November 30 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was up.
Published:
Last Updated:
Brokerage firm Jefferies has released its top pharmaceutical picks for the coming year and what to expect.
Published:
Last Updated:
The Franchise Picks list makes sense for solid growth investors looking for total return. Many of the stocks pay good dividends and have upside price potential.
Published:
Last Updated:
Tuesday's top analyst upgrades, downgrades and initiations include AbbVie, CDW, CSC, Eli Lilly, Ericsson, Gold Fields, JD.com, Nokia and Rackspace.
Published:
Last Updated:
Buying high-yielding blue chips for 2016 makes good sense. The Federal Reserve interest rate increases over the next two years are expected to remain very small and very measured.
Published:
Last Updated:
You may want to avoid these stocks over the next few months.
Published:
Last Updated:
Jefferies has updated the thesis behind its "Top 5 for 2015" pharmaceutical stock picks
Published:
Last Updated:
The short interest data have been released for the October 30 settlement date, and for most of the selected pharmaceutical stocks, short interest was down.
Published:
Last Updated:
Buying stocks such as these, with solid growth potential and paying dividends higher than the 10-year Treasury debt, makes good sense now.
Published:
Last Updated: